Alterity Therapeutics Limited Stock Nasdaq
Stocks
ATHE
US02155X2053
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Nasdaq
00:54:00 21/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 4.470 USD | -6.88% |
|
-4.89% | +45.13% |
| Market Cap | 77.43M 66.3M 61.86M 56.76M 107M 7.41B 109M 734M 286M 3.71B 291M 284M 12.29B | P/E 2026 * |
-0.38x | P/E 2027 * | -0.38x |
|---|---|---|---|---|---|
| Enterprise Value | 32.18M 27.55M 25.71M 23.59M 44.32M 3.08B 45.2M 305M 119M 1.54B 121M 118M 5.11B | EV / Sales 2026 * |
11.7x | EV / Sales 2027 * | 17.5x |
| Free-Float |
91.94% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Limited
| 1 day | -6.88% | ||
| 1 week | -4.89% | ||
| Current month | +1.25% | ||
| 1 month | -5.70% | ||
| 3 months | +4.68% | ||
| 6 months | +35.45% | ||
| Current year | +45.13% |
| 1 week | 4.31 |  | 4.9 |
| 1 month | 4.2 | | 5.04 |
| Current year | 3.02 | | 5.89 |
| 1 year | 2.66 | | 5.89 |
| 3 years | 1 | | 7 |
| 5 years | 1 | | 14 |
| 10 years | 1 | | 57.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
Abby Macnish
DFI | Director of Finance/CFO | - | 30/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.88% | -4.89% | - | - | 78.2M | |
| +1.14% | +2.27% | +2.38% | +24.66% | 50.5B | |
| -2.62% | +3.91% | +480.49% | +602.73% | 46.01B | |
| -1.18% | +4.85% | +20.68% | +90.34% | 42.85B | |
| +3.93% | +7.40% | +35.07% | +21.01% | 41.03B | |
| 0.00% | -3.91% | +17.87% | +47.98% | 32.02B | |
| +1.88% | +6.58% | +33.18% | +152.15% | 16.98B | |
| -0.95% | +4.93% | - | - | 17.05B | |
| +3.06% | +3.88% | +5.81% | +35.45% | 14.3B | |
| +1.79% | +5.08% | +85.22% | +47.12% | 13.84B | |
| Average | +0.04% | +2.01% | +85.09% | +127.68% | 30.51B | |
| Weighted average by Cap. | +0.52% | +2.37% | +104.65% | +151.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.74M 2.35M 2.19M 2.01M 3.78M 263M 3.86M 26.01M 10.14M 132M 10.31M 10.08M 436M | 2.09M 1.79M 1.67M 1.53M 2.88M 200M 2.94M 19.81M 7.72M 100M 7.85M 7.68M 332M |
| Net income | -14.76M -12.64M -11.79M -10.82M -20.34M -1.41B -20.74M -140M -54.54M -708M -55.43M -54.23M -2.34B | -29.99M -25.68M -23.96M -21.98M -41.31M -2.87B -42.12M -284M -111M -1.44B -113M -110M -4.76B |
| Net Debt | -45.25M -38.75M -36.15M -33.17M -62.33M -4.33B -63.56M -429M -167M -2.17B -170M -166M -7.18B | -40.9M -35.02M -32.67M -29.98M -56.34M -3.91B -57.45M -388M -151M -1.96B -154M -150M -6.49B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/08/26 | US$4.470 | -6.88% | 7,984 |
| 19/08/26 | US$4.800 | +5.20% | 43,608 |
| 18/08/26 | US$4.563 | -0.16% | 9,441 |
| 17/08/26 | US$4.570 | -4.59% | 30,833 |
| 14/08/26 | US$4.790 | +1.91% | 7,457 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
- ATHE Stock
Select your edition
All financial news and data tailored to specific country editions
